New Alzheimer's medication slows decline, Says New Study
New Alzheimer's medication slows decline, Says New Study

New Alzheimer’s medication slows decline, Says New Study.

An experimental drug being tested to see if it can treat Alzheimer’s disease helped slow the inevitable loss of clear thinking and memory that comes with the condition, researchers reported Wednesday.

It’s a rare success in a field littered with failures. No drug has yet been shown to reverse the symptoms of Alzheimer’s, which affects more than 5 million Americans and has no cure.

And this one is no home run. Everyone who took the drug continued to get worse. But those who got the highest doses got worse more slowly.

“We had a 47 percent reduction in decline at 18 months,” Dr. Lynn Kramer, chief medical officer of the neurology division of drug company Eisai, told reporters.

It was the second piece of good news on the Alzheimer’s front. Earlier Wednesday, researchers reported that lowering blood pressure to recommended levels was safe and reduced the rate of mild cognitive impairment — a precursor of dementia — by 20 percent.

Eisai and its U.S. partner Biogen presented results to an eager audience at the Alzheimer’s Association annual meeting in Chicago Wednesday.

They’ve been treating more than 800 patients with early-stage Alzheimer’s with various doses of the drug, called BAN2401. It’s a monoclonal antibody, a lab-engineered immune system protein designed to remove amyloid plaques from the brain.

One leading theory about Alzheimer’s is that these amyloid clogs cause the disease.

“This is the first large trial to support the amyloid hypothesis,” Kramer said.

The drug cleared the plaques from the brains of the patients, by 93 percent at the highest dose.

Dr. James Hendrix, director of global science initiatives at the Alzheimer’s Association, says the findings are significant.

“Not only do we see a slowing in the rate of cognitive decline, we also see that reduction of amyloid burden in the brain as measured by amyloid PET (imaging)”, Hendrix told NBC News. “That biomarker confirmation really adds confidence that what you are seeing in the primary measure is real.”

Still, the researchers had to tweak the results to be able to declare a success. When the trial was at the 12 month point, they said, they didn’t see a benefit. Now, after their patients have been infused with the drug for 18 months, they say they can see an effect.

To find out more, Hendrix said, the companies will have to design an advanced trial called a Phase 3 clinical trial — the final stage before seeking full Food and Drug Administration approval.

LEAVE A REPLY

Please enter your comment!
Please enter your name here